(Q45959057)

18 December 2017

title

Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. (English)

1 reference

18 December 2017

1 reference

Richard D O'Connor

1

1 reference

18 December 2017

Jacqueline R Carranza Rosenzweig

2

1 reference

18 December 2017

Richard H Stanford

3

1 reference

18 December 2017

Amanda S Gilmore

4

1 reference

18 December 2017

Kira L Ryskina

5

1 reference

18 December 2017

Antonio P Legorreta

6

1 reference

18 December 2017

David A Stempel

7

1 reference

18 December 2017

publication date

1 December 2005

1 reference

18 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

18 December 2017

volume

95

1 reference

18 December 2017

issue

6

1 reference

18 December 2017

page(s)

535-540

1 reference

18 December 2017

Trends in the cost of illness for asthma in the United States, 1985-1994

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

The health economics of asthma and rhinitis. I. Assessing the economic impact

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Asthma in the United States: burden and current theories

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

A national estimate of the economic costs of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Relationship between asthma drug therapy patterns and healthcare utilization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Low-dose inhaled corticosteroids and the prevention of death from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Long-term effects of budesonide or nedocromil in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Outcomes of a population-based asthma management program: quality of life, absenteeism, and utilization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

Compliance with US asthma management guidelines and specialty care: a regional variation or national concern?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961015-0

7 January 2021

10.1016/S1081-1206(10)61015-0

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017